Tag #Glp-1 Receptor Agonists

Showing 1 to 12 of 17 results

elpais.com

🌐 85% Global Worthiness

Sep 18, 10:18

Japanese Study Reveals Psychological Factors Impacting Weight-Loss Drug Efficacy

A Japanese study of 92 diabetic patients found that individuals who overeat in response to palatable food respond better to GLP-1 agonist drugs than those who overeat due to emotional reasons, highlighting the importance of psychological factors in weight loss.

Japanese Study Reveals Psychological Factors Impacting Weight-Loss Drug Efficacy

A Japanese study of 92 diabetic patients found that individuals who overeat in response to palatable food respond better to GLP-1 agonist drugs than those who overeat due to emotional reasons, highlighting the importance of psychological factors in weight loss.

Progress

20% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How do the findings of this study relate to broader understanding and treatment of obesity?

The study supports a more nuanced view of obesity, suggesting that classifying obesity by physiological and behavioral phenotypes, not just BMI, is crucial. This approach indicates the need for personalized treatments combining medication and psychotherapy, addressing both physical and psychological aspects.

euronews.com

🌐 75% Global Worthiness

Sep 14, 10:17

High Dropout Rate Among Weight Loss Drug Users

A new analysis reveals that 52 percent of over 77,000 people using anti-obesity drugs in Denmark stopped within a year, raising concerns about long-term adherence and highlighting socioeconomic disparities in access.

High Dropout Rate Among Weight Loss Drug Users

A new analysis reveals that 52 percent of over 77,000 people using anti-obesity drugs in Denmark stopped within a year, raising concerns about long-term adherence and highlighting socioeconomic disparities in access.

Progress

20% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What factors contribute to the high discontinuation rates observed in the study?

Several factors influenced discontinuation. Younger age (under 30), lower socioeconomic status (those in low-income areas were 14 percent more likely to quit), male gender, pre-existing chronic health issues, and prior use of gastrointestinal or psychiatric medications were all associated with increased likelihood of stopping treatment. High drug costs, as exemplified by Ozempic's price difference between Denmark and Germany, were also implicated.

abcnews.go.com

🌐 85% Global Worthiness

Jul 7, 13:15

High Costs, Inconsistent Coverage Limit Access to Popular Obesity Drugs

High prices and inconsistent insurance coverage limit access to the popular obesity medications Wegovy and Ozempic, despite falling costs and some employer-sponsored plans expanding coverage; the medications cost around $500 per month without insurance, forcing doctors to find creative solutions and...

High Costs, Inconsistent Coverage Limit Access to Popular Obesity Drugs

High prices and inconsistent insurance coverage limit access to the popular obesity medications Wegovy and Ozempic, despite falling costs and some employer-sponsored plans expanding coverage; the medications cost around $500 per month without insurance, forcing doctors to find creative solutions and...

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the immediate impacts of high costs and inconsistent insurance coverage for Wegovy and Ozempic on patient access and treatment?

Despite falling prices, Wegovy and Ozempic, popular obesity treatments, remain inaccessible to many due to high costs ($500/month without insurance). Even with insurance, coverage is inconsistent, forcing doctors to find creative solutions. High costs are driven by the drugs' popularity, with Wegovy having 200,000 weekly prescriptions and Zepbound generating $2.3 billion in first-quarter sales.

dailymail.co.uk

🌐 85% Global Worthiness

Jun 3, 19:18

Ozempic Weight Loss Drugs Linked to Increased Kidney Cancer Risk

A major study of 86,000 patients revealed that while weight-loss drugs like Ozempic lower the risk of 16 cancers by 17 percent, they may increase kidney cancer risk by 33 percent, prompting calls for further research.

Ozempic Weight Loss Drugs Linked to Increased Kidney Cancer Risk

A major study of 86,000 patients revealed that while weight-loss drugs like Ozempic lower the risk of 16 cancers by 17 percent, they may increase kidney cancer risk by 33 percent, prompting calls for further research.

Progress

60% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the immediate implications of the observed increased kidney cancer risk associated with weight-loss drugs like Ozempic, considering the drug's overall cancer risk reduction?

A large-scale study of 86,000 obese or overweight patients found that while weight-loss drugs like Ozempic reduced the risk of 16 cancers by 17 percent overall, they were associated with a 33 percent increased risk of kidney cancer. This concerning trend warrants further investigation, as the study was observational and doesn't prove causality.

dailymail.co.uk

🌐 85% Global Worthiness

Apr 7, 19:16

Semaglutide Linked to Reduced Dementia Risk in Major Studies

Two large-scale studies suggest that the weight-loss drug semaglutide, found in Wegovy and Ozempic, may significantly lower the risk of developing dementia, offering a potential preventative measure against a condition costing the UK £42 billion annually.

Semaglutide Linked to Reduced Dementia Risk in Major Studies

Two large-scale studies suggest that the weight-loss drug semaglutide, found in Wegovy and Ozempic, may significantly lower the risk of developing dementia, offering a potential preventative measure against a condition costing the UK £42 billion annually.

Progress

32% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the significance of the finding that semaglutide may reduce dementia risk?

Two major studies suggest that semaglutide, the active ingredient in Wegovy and Ozempic, may significantly reduce the risk of developing dementia. A University of Florida study analyzed 396,963 individuals with type 2 diabetes and found that semaglutide, among other GLP-1 receptor agonists, was associated with a decreased risk of dementia compared to other diabetes medications. A separate Irish study, analyzing 26 clinical trials, also found a statistically significant reduction in dementia risk linked to GLP-1RAs.

dw.com

🌐 75% Global Worthiness

Jan 27, 13:09

Diabetes Drugs Linked to Reduced Risk of Mental Health Issues

A study of 1.2 million veterans' medical records found that the diabetes and weight-loss drugs Ozempic and Wegovy (GLP-1 receptor agonists) may be linked to a reduced risk of various mental health issues, including alcohol and substance use disorders, suicidal thoughts, schizophrenia, dementia, and ...

Diabetes Drugs Linked to Reduced Risk of Mental Health Issues

A study of 1.2 million veterans' medical records found that the diabetes and weight-loss drugs Ozempic and Wegovy (GLP-1 receptor agonists) may be linked to a reduced risk of various mental health issues, including alcohol and substance use disorders, suicidal thoughts, schizophrenia, dementia, and ...

Progress

24% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the long-term implications of this study, and what additional research is needed to explore potential therapeutic uses of GLP-1 RAs for mental health conditions?

Future research should focus on randomized controlled trials to confirm these findings and investigate the underlying mechanisms. The study's limitations, such as the predominantly white male veteran population, highlight the need for further investigation across diverse populations to determine the generalizability of these results. Understanding the precise impact of GLP-1 RAs on different neurological pathways will be crucial for potential therapeutic applications.

theguardian.com

🌐 85% Global Worthiness

Sep 17, 01:17

Orforglipron: A New Daily Pill for Weight Loss Shows Promising Results

A 72-week trial of 3,127 obese adults found that orforglipron, a new daily weight-loss pill, led to significant weight loss, with 18.4% of those on the highest dose losing 20% or more of their body weight.

Orforglipron: A New Daily Pill for Weight Loss Shows Promising Results

A 72-week trial of 3,127 obese adults found that orforglipron, a new daily weight-loss pill, led to significant weight loss, with 18.4% of those on the highest dose losing 20% or more of their body weight.

Progress

44% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the potential implications and future considerations regarding orforglipron?

Orforglipron's potential approval by the FDA and other regulatory bodies could greatly expand access to effective weight-loss treatment for millions. However, longer-term studies are necessary to assess the long-term effects and potential side effects, ensuring its safety and efficacy over extended periods.

zeit.de

🌐 85% Global Worthiness

Aug 8, 16:18

Eli Lilly's Orforglipron Shows Promise in Weight Loss Trial

Eli Lilly's Phase 3 trial of Orforglipron, an oral GLP-1 receptor agonist for weight loss, showed a 12.4% average weight loss in obese adults after 72 weeks, prompting plans for FDA approval by year's end; however, experts voice concerns about the yo-yo effect and lack of comparison to effective non...

Eli Lilly's Orforglipron Shows Promise in Weight Loss Trial

Eli Lilly's Phase 3 trial of Orforglipron, an oral GLP-1 receptor agonist for weight loss, showed a 12.4% average weight loss in obese adults after 72 weeks, prompting plans for FDA approval by year's end; however, experts voice concerns about the yo-yo effect and lack of comparison to effective non...

Progress

44% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the significance of Eli Lilly's successful Phase 3 trial for Orforglipron, and what are its immediate implications for weight management?

Eli Lilly's Orforglipron, a new oral GLP-1 receptor agonist, showed a 12.4% average weight loss in obese adults over 72 weeks in a Phase 3 trial, compared to 0.9% in the placebo group. The company plans to seek FDA approval by year's end, offering an alternative to injectable treatments. Common side effects included nausea, constipation, diarrhea, and vomiting.

dailymail.co.uk

🌐 85% Global Worthiness

Jun 5, 19:14

Ozempic Linked to Doubled Risk of Blinding Eye Condition

An Israeli study of 139,000 type 2 diabetes patients found those using Ozempic or similar weight-loss drugs were twice as likely to develop the blinding eye condition neovascular age-related macular degeneration (nAMD) compared to a control group, prompting further research into the drugs' potential...

Ozempic Linked to Doubled Risk of Blinding Eye Condition

An Israeli study of 139,000 type 2 diabetes patients found those using Ozempic or similar weight-loss drugs were twice as likely to develop the blinding eye condition neovascular age-related macular degeneration (nAMD) compared to a control group, prompting further research into the drugs' potential...

Progress

60% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How does the study's methodology and findings contribute to our understanding of the potential causal link between GLP-1 receptor agonists and nAMD?

The study, published in JAMA Opthalmology, analyzed 139,000 type 2 diabetes patients, with roughly 46,000 using Ozempic or similar drugs. Over three years, the Ozempic group experienced 93 nAMD cases (0.2 percent), versus 88 cases (0.1 percent) in the control group. The increased risk is possibly linked to GLP-1 receptors in the eye, triggering blood vessel growth.

theglobeandmail.com

🌐 85% Global Worthiness

May 1, 16:13

WHO to Officially Endorse Weight-Loss Drugs for Obesity Treatment

The World Health Organization will officially endorse weight-loss drugs like Wegovy and Mounjaro for adult obesity treatment in August, addressing the over 1 billion people affected globally, with 70% in low- and middle-income countries, while acknowledging high costs and advocating for increased ac...

WHO to Officially Endorse Weight-Loss Drugs for Obesity Treatment

The World Health Organization will officially endorse weight-loss drugs like Wegovy and Mounjaro for adult obesity treatment in August, addressing the over 1 billion people affected globally, with 70% in low- and middle-income countries, while acknowledging high costs and advocating for increased ac...

Progress

32% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the WHO's decision regarding weight-loss drugs for obesity treatment, and what are its immediate implications for global health?

The World Health Organization (WHO) will officially endorse weight-loss drugs like Wegovy and Mounjaro to treat adult obesity, marking a significant shift in its approach to this global health issue. This decision follows clinical trials showing 15-20% weight loss and considers the over 1 billion people globally affected by obesity, with 70% residing in low- and middle-income countries.

dw.com

🌐 75% Global Worthiness

Jan 31, 22:08

Ozempic and Wegovy May Reduce Risk of Multiple Diseases: Large-Scale Study

A study of 1.2 million veterans' health records suggests that Ozempic and Wegovy, GLP-1 receptor agonists, may reduce risks of schizophrenia, Alzheimer's, and substance abuse, although further research is needed due to the study's limitations.

Ozempic and Wegovy May Reduce Risk of Multiple Diseases: Large-Scale Study

A study of 1.2 million veterans' health records suggests that Ozempic and Wegovy, GLP-1 receptor agonists, may reduce risks of schizophrenia, Alzheimer's, and substance abuse, although further research is needed due to the study's limitations.

Progress

52% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the key findings of this study regarding the impact of Ozempic and Wegovy on various health risks?

A large-scale study of 1.2 million medical records indicates that popular diabetes and weight-loss drugs, Ozempic and Wegovy, may reduce the risk of other diseases, including schizophrenia and Alzheimer's, by 18% and 12%, respectively. The study also showed a 10% reduction in suicidal thoughts or self-harm.

dw.com

🌐 75% Global Worthiness

Jan 27, 13:09

GLP-1RA Drugs Show Potential Link to Reduced Risk of Mental Health and Cognitive Conditions

A study of over 1.2 million veterans' medical records suggests a possible link between GLP-1 receptor agonist drugs, such as Ozempic and Wegovy, and a reduced risk of various mental health conditions, including suicidal thoughts, schizophrenia, dementia, and Alzheimer's disease, although further res...

GLP-1RA Drugs Show Potential Link to Reduced Risk of Mental Health and Cognitive Conditions

A study of over 1.2 million veterans' medical records suggests a possible link between GLP-1 receptor agonist drugs, such as Ozempic and Wegovy, and a reduced risk of various mental health conditions, including suicidal thoughts, schizophrenia, dementia, and Alzheimer's disease, although further res...

Progress

44% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How might the mechanisms of action of GLP-1RA drugs explain their potential impact on mental health and addiction?

The observed association between GLP-1RA use and reduced risk of mental health and cognitive decline issues may be linked to the drugs' impact on brain receptors involved in impulse control and reward. This is an observational study, however, so it doesn't establish causality, and further research is needed to confirm these findings and understand the underlying mechanisms.

Showing 1 to 12 of 17 results